{"filings":[{"id":499038,"accession_number":"0001193125-26-228902","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-18T20:06:05+00:00","items":["1.01","2.03","3.02","8.01","9.01"],"status":"ready","headline":"Mirum issues $690M zero-coupon convertible notes due 2032; exchanges $237M of 2029 notes","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $690M aggregate principal of 0.00% Convertible Senior Notes due 2032, including $90M option exercise.","Initial conversion price ~$138.94 per share, a 30% premium over $106.88 closing price on pricing date.","Concurrently exchanged ~$237.2M of existing 4.00% 2029 notes for $475M cash and ~3.22M shares.","Net proceeds ~$671.6M; remainder for general corporate purposes and potential acquisitions.","Notes mature June 1, 2032; redeemable after June 6, 2029 under stock price conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95254,"accession_number":"0001759425-26-000036","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 net sales $159.9M, raises FY guidance to $660-680M; volixibat & brelovitug meet primary endpoints","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2026 net product sales $159.9M, up 43% YoY; LIVMARLI $113.8M (+55%), Bile Acid Medicines $46.1M (+20%).","Full-year 2026 net product sales guidance raised to $660-680M from prior range.","Volixibat VISTAS Phase 2b in PSC met primary endpoint; NDA submission expected H2 2026.","Brelovitug AZURE-1 Phase 2b in HDV met primary endpoint; Phase 3 enrollment complete, topline H2 2026.","In-licensed zilurgisertib for FOP from Incyte for $16M upfront; FDA Priority Review, PDUFA Sept 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":159882000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95253,"accession_number":"0001193125-26-202609","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's volixibat meets primary endpoint in PSC Phase 2b VISTAS study with statistically significant itch reduction","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Volixibat showed 2.72 point improvement in pruritus vs 1.08 for placebo; placebo-adjusted difference 1.64 (p<0.0001).","55.6% of volixibat patients achieved ≥2 point reduction in Adult ItchRO vs 26.3% for placebo (p=0.0019).","Pre-NDA meeting with FDA scheduled summer 2026; NDA submission planned H2 2026.","VANTAGE Phase 2b study in PBC top-line data now expected Q1 2027.","Most common adverse event was diarrhea (40.3% volixibat vs 8.6% placebo); SAEs in volixibat group not considered related."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95252,"accession_number":"0001193125-26-179048","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-04-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's brelovitug meets Phase 2b primary endpoint in chronic HDV; 100% virologic response at 300 mg QW","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% of patients on 300 mg QW and 75% on 900 mg Q4W achieved virologic response vs 0% control.","Primary composite endpoint (virologic response + ALT normalization) reached by 45% and 35% vs 0% control (p=0.003, 0.024).","Brelovitug was well tolerated; no discontinuations, low grade 3+ events, no related serious AEs.","Full Phase 2b results to be presented at EASL Congress May 27-30, 2026.","Phase 3 topline data from AZURE-1/4 expected H2 2026; potential U.S. BLA submission in 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95251,"accession_number":"0001759425-26-000021","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K/A","filed_at":"2026-04-08T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Mirum completes acquisition of Bluejay Therapeutics with $268.5M PIPE; Bluejay reports 2025 net loss of $101.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Concurrent PIPE raised $268.5M gross at $68.48/sh including pre-funded warrants.","Bluejay 2025 audited: net loss $101.7M, R&D $87.1M, total assets $85.6M, accumulated deficit $190M.","Bluejay had substantial doubt about going concern; Mirum committed to fund operations post-close.","Lead candidate brelovitug (BJT-778) for chronic hepatitis delta is in clinical development.","Pro forma financials for combined entity filed; acquisition closed Jan 23, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108171,"accession_number":"0001759425-26-000010","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Pharma 2025 sales $521M (+55% YoY); guides 2026 $630-650M; multiple pipeline readouts in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2025 net product sales $521.3M, up from $336.4M in 2024 (+55% YoY). LIVMARLI US sales $244.7M (+69% YoY).","2026 guidance: global net product sales $630-650M, reflecting continued growth.","Pipeline catalysts: Volixibat VISTAS (PSC) topline Q2 2026; Livmarli EXPAND data Q4 2026; Brelovitug HDV data H2 2026.","Completed acquisition of Bluejay Therapeutics for brelovitug; raised $268.5M in private placements.","Cash and investments $391.4M as of Dec 31, 2025; operating expenses $543.4M (incl. $95M non-cash)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":521312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108170,"accession_number":"0001193125-26-022582","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["2.01","7.01","8.01","9.01"],"status":"ready","headline":"Mirum acquires Bluejay for $280.8M cash + stock; adds late-stage HDV therapy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront consideration $280.8M cash plus ~4.67M shares; holdback $25.8M plus ~0.52M shares; up to $200M milestones.","Added brelovitug (anti-HDV mAb) with FDA Breakthrough Therapy and EMA PRIME; Phase 3 AZURE topline data expected 2H 2026.","Concurrent private placements raised ~$268.5M gross proceeds to support brelovitug development and commercial activities.","Mirum also acquired Bluejay's net cash of ~$56.6M.","Entities affiliated with Frazier Life Sciences (board member >5% holder) received pro rata portion of consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108169,"accession_number":"0001759425-26-000004","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Mirum prelim 2025 sales ~$520M, above guidance; 2026 outlook $630-650M; acquiring Bluejay for HDV","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary 2025 net product sales ~$520M, exceeding upper end of guidance.","2026 guidance: global net sales $630M-$650M; positive cash flow from operations in 2025.","LIVMARLI 2025 sales ~$359M (US $243M, +69% YoY); CHOLBAM/CTEXLI ~$161M (+31% YoY).","Proposed acquisition of Bluejay Therapeutics (brelovitug for HDV) expected close late Jan 2026; $268.5M private placements.","Pipeline: volixibat PSC topline Q2 2026; LIVMARLI EXPAND topline Q4 2026; HDV AZURE data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":521312000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124599,"accession_number":"0001193125-25-326822","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum Pharmaceuticals sues Sandoz, Annora, Zydus, Zenara over generic Livmarli ANDAs","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Received Paragraph IV notice letters from Sandoz, Annora Pharma, Zydus Lifesciences, and Zenara Pharma seeking generic Livmarli.","Filed patent infringement suits on December 19, 2025 in U.S. District Court for Delaware.","Suits assert infringement of Orange Book patents for LIVMARLI (maralixibat).","Suits seek FDA approval no earlier than expiration of last asserted patent.","30-month stay prevents FDA from granting final approval of the ANDAs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124598,"accession_number":"0001193125-25-325825","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Mirum Pharmaceuticals secures additional $68.5M PIPE from TCGX ahead of Bluejay acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["1,000,000 shares at $68.48/share; ~$68.5M gross proceeds from TCGX.","Combined with Dec 2025 $200M PIPE raises total ~$268.5M to fund Bluejay acquisition.","Both PIPE and Bluejay acquisition expected to close in Q1 2026, subject to conditions.","Registration rights agreement provides for resale registration of the PIPE shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124597,"accession_number":"0001193125-25-310611","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mirum pays $250M cash and up to 5.2M shares (≈$370M) at closing, plus up to $200M in milestone payments for Bluejay Therapeutics.","Acquisition adds brelovitug, a Phase 3 monoclonal antibody for chronic hepatitis D (HDV) with Breakthrough Therapy and PRIME designations.","Mirum also raised $200M in a PIPE from investors including Morgan Stanley, Leerink, Cantor, Raymond James, and Citizens JMP.","Top-line Phase 3 data for brelovitug expected in second half of 2026; BLA submission anticipated in first half of 2027.","Transaction expected to close in Q1 2026, subject to HSR clearance, stockholder approval, and other customary conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124596,"accession_number":"0001759425-25-000057","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum receives Sandoz Paragraph IV notice challenging Livmarli patents; plans to sue","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Sandoz filed ANDA seeking FDA approval for generic Livmarli (maralixibat).","Sandoz alleges five Livmarli Orange Book patents are invalid or not infringed.","Mirum has 45 days to sue, triggering a 30-month FDA approval stay.","Mirum expects additional Paragraph IV notices from other ANDA filers.","Company vows to vigorously enforce IP and seek a permanent injunction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124595,"accession_number":"0001759425-25-000053","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q3 revenue $133M, up 47% YoY; lifts FY guidance to $500-510M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 total revenue $133.0M vs $90.4M in Q3 2024; LIVMARLI sales $92.2M (+56% YoY).","Bile Acid Medicines net sales $40.8M, up 31% YoY; cash and investments $378M.","Volixibat VISTAS (PSC) enrollment complete; topline data expected Q2 2026.","Volixibat VANTAGE (PBC) and LIVMARLI EXPAND enrollment expected 2026; topline H1 2027.","Phase 2 study of MRM-3379 for Fragile X Syndrome initiated."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":372380000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141266,"accession_number":"0001759425-25-000040","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q2 revenue $127.8M; raises FY 2025 guidance to $490-510M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 global net product sales $127.8M, up 64% YoY from $77.9M.","LIVMARLI sales $88.2M (+87% YoY); Bile Acid Medicines $39.6M (+30%).","FY 2025 revenue guidance raised to $490-510M from prior range.","Cash $321.7M; volixibat VISTAS topline expected Q2 2026.","MRM-3379 Phase 2 in Fragile X expected Q4 2025 initiation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":239370000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159077,"accession_number":"0001759425-25-000034","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Mirum Pharmaceuticals 2025 Annual Meeting results: three directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Class III directors elected: Laura Brege (17.97M for, 18.17M withheld), Michael Grey (30.78M for), Christopher Peetz (35.98M for).","Ratified Ernst & Young as independent auditor for FY2025: 43.12M for, 19.2K against, 19.4K abstentions.","Advisory vote on executive compensation approved: 34.67M for, 1.46M against, 8.9K abstentions.","Broker non-votes of 7.02M on director elections and compensation proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159076,"accession_number":"0001759425-25-000030","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 revenue $111.6M; raises 2025 guidance to $435-450M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 total revenue $111.6M vs $69.2M YoY, driven by LIVMARLI ($73.2M, +71%) and Bile Acid Medicines ($38.4M, +47%).","Raises full-year 2025 revenue guidance to $435-450M from prior range.","LIVMARLI oral tablet formulation approved by FDA; also approved in Japan for ALGS and PFIC.","VISTAS PSC study enrollment completion expected Q3 2025; topline data Q2 2026.","Cash and investments $298.6M as of March 31, 2025, up from $292.8M at year-end 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.3,"consensus_revenue_estimate":null,"consensus_revenue_actual":111585000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177524,"accession_number":"0001759425-25-000012","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports 2024 net product sales $336.4M; guides 2025 sales $420M-$435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["2024 net product sales $336.4M, up from $178.9M in 2023; LIVMARLI sales $213.3M, Bile Acid Medicines $123.1M.","2025 global net product sales guidance of $420M to $435M; expects positive cash flow.","Volixibat VISTAS PSC study expected to complete enrollment H2 2025; topline data in 2026.","Cash, equivalents and investments $292.8M as of Dec 31, 2024 (vs $286.3M end 2023).","CTEXLI (chenodiol) approved in US for cerebrotendinous xanthomatosis; MRM-3379 Phase 2 in FXS expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":336888000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177523,"accession_number":"0001759425-25-000003","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Mirum Pharma 2024 net sales ~$336M, above guidance; 2025 outlook $420-435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary unaudited FY2024 net product sales ~$336M, exceeding upper end of guidance range.","LIVMARLI net sales ~$213M; CHOLBAM/CHENODAL ~$123M; Q4 2024 sales ~$99M.","2025 guidance: global net product sales $420-435M with positive cash flow from operations.","Year-end cash and investments ~$287M; achieved positive cash from operations in Q3 2024.","Pipeline: PDUFA date for chenodiol in CTX March 28, 2025; volixibat VISTAS enrollment completion H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":336888000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194242,"accession_number":"0001759425-24-000037","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.","Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.","PDUFA date for chenodiol in CTX set for Dec 28, 2024.","Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.","In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":237474000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210569,"accession_number":"0001759425-24-000029","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q2 net product sales $77.8M (+139% YoY); LIVMARLI sales $47.2M; positive volixibat interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 global net product sales $77.8M, up 139% vs Q2 2023; full-year guidance reaffirmed at $310-320M.","LIVMARLI net sales $47.2M (+45% YoY); combined CHOLBAM/CHENODAL sales $30.5M.","Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies.","LIVMARLI approved in Europe for PFIC (≥3 months) and US label expanded to ≥12 months; NDA filed for chenodiol in CTX.","Cash & investments $295.4M (Dec 2023: $286.3M); operating expenses $102.1M vs $61.8M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":147097000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228896,"accession_number":"0001193125-24-162056","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum reports positive interim Ph2b data for volixibat in PBC and PSC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.","Significant fatigue improvement at week 16; no new safety signals; diarrhea (77%) mostly mild/moderate and transient; 4 SAEs (1 placebo).","VANTAGE and VISTAS PSC trials to continue with volixibat 20 mg twice daily; independent data review committee recommended continuation for PSC.","No clinically meaningful changes in liver biomarkers in PBC; sponsor remains blinded to interim results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228895,"accession_number":"0001759425-24-000023","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect all three Class II directors, ratify auditor, approve say-on-pay, set frequency to one year","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Laurent Fischer, Patrick Heron, and Saira Ramasastry as Class II directors (each received >19M votes for).","Ratified Ernst & Young as independent auditor for FY2024 (37.5M for, 36k against, 143k abstain).","Advisory approval of executive compensation: 32.7M for, 1.1M against, 90k abstain.","Advisory vote on say-on-pay frequency: 33.8M for one year; board adopts annual frequency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228894,"accession_number":"0001193125-24-151965","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-05-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Mirum's LIVMARLI gets positive CHMP opinion for PFIC; EC decision in Q3 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted positive opinion for LIVMARLI (maralixibat) to treat PFIC in patients aged 3 months and older.","CHMP concluded LIVMARLI provides significant clinical benefit vs already-approved PFIC treatment.","COMP recommended maintaining Orphan Drug Designation for LIVMARLI in PFIC.","European Commission decision on marketing authorization expected in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228893,"accession_number":"0001759425-24-000017","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum Q1 revenue $69.2M, up 119% YoY; reaffirms FY guidance $310-320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Global product sales net $68.9M, up 137% vs Q1 2023; LIVMARLI net sales $42.8M (+47%).","FDA approved LIVMARLI for PFIC cholestatic pruritus in March 2024.","Volixibat interim analyses (VISTAS/VANTAGE) expected June 2024; CHENODAL NDA for CTX on track H1 2024.","Cash and equivalents $302.8M as of March 31, 2024, up from $286.3M at year-end 2023.","Operating expenses $95.7M (incl. $17.1M non-cash items) vs $58.7M in prior-year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":69222000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247532,"accession_number":"0001759425-24-000005","cik":1759425,"company_name":"Mirum Pharmaceuticals, Inc.","ticker":"MIRM","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Mirum reports 2023 net product sales of $178.9M (+142% YoY); guides 2024 sales $310-320M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2023 total revenue $186.4M, up 142% over 2022; LIVMARLI net sales $141.8M (+89% YoY).","2024 global net product sales guidance of $310M to $320M, reflecting continued growth across approved medicines.","LIVMARLI PFIC PDUFA date on track for March 13, 2024; CHENODAL NDA for CTX planned H1 2024.","Volixibat VISTAS (PSC) and VANTAGE (PBC) interim analyses expected in first half 2024.","Appointed Joanne Quan, M.D. as Chief Medical Officer; cash and equivalents $286.3M as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":186374000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6003906903.653088,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}